Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 9/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.41 |
| ▸ | UCHL1 | P09936 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3919921 | 1.00 | HCRTR1 (0.48) | HCRTR1HCRTR2USP30UCHL1POLB | |
| SCHEMBL4917573 | 0.95 | HCRTR1 (0.43) | HCRTR1HCRTR2USP30UCHL1 | |
| SCHEMBL4917565 | 0.95 | HCRTR1 (0.43) | HCRTR1HCRTR2USP30UCHL1 | |
| SCHEMBL3916610 | 0.87 | HCRTR1 (0.53) | HCRTR1HCRTR2USP30UCHL1POLB | |
| SCHEMBL3916612 | 0.87 | HCRTR1 (0.53) | HCRTR1HCRTR2USP30UCHL1POLB | |
| SCHEMBL3852302 | 0.86 | HCRTR1 (0.50) | HCRTR1HCRTR2USP30UCHL1POLB | |
| SCHEMBL3852298 | 0.86 | HCRTR1 (0.50) | HCRTR1HCRTR2USP30UCHL1POLB | |
| SCHEMBL3853950 | 0.85 | HCRTR1 (0.64) | HCRTR1HCRTR2USP30UCHL1POLB | |
| SCHEMBL3853946 | 0.85 | HCRTR1 (0.64) | HCRTR1HCRTR2USP30UCHL1POLB | |
| SCHEMBL3922427 | 0.85 | HCRTR1 (0.49) | HCRTR1HCRTR2USP30UCHL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869032-B8 | PYRIMIDINE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-03-25 | — | — | EP | disclosed |
| EP-1869032-B1 | PYRIMIDINE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2008-08-13 | — | — | EP | disclosed |
| US-20080171742-A1 | 4-(Pyrid-2-Yl) Amino Substituted Pyrimidine as Protein Kinase Inhibitors | ASRAZENECA (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080167297-A1 | Pyrimidine Derivatives for Use as Anticancer Agents | ASTRAZENECA AB (SE) | 2008-07-10 | — | — | US | disclosed |
| EP-1871771-A1 | 4-(PYRID-2-YL) AMINO SUBSTITUTED PYRIMIDINE AS PROTEIN KINASE INHIBITORS | AstraZeneca AB (SE) | 2008-01-02 | — | — | EP | disclosed |
| EP-1869032-A1 | PYRIMIDINE DERIVATIVES FOR USE AS ANTICANCER AGENTS | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006109026-A1 | 4-(PYRID-2-YL) AMINO SUBSTITUTED PYRIMIDINE AS PROTEIN KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006106307-A1 | PYRIMIDINE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167297-A1 | Pyrimidine Derivatives for Use as Anticancer Agents | IGF1R, TYMP, IGFBP1 | HCRTR1 4170/4885HCRTR2 4357/4885USP30 4439/4885 |
| US-20080171742-A1 | 4-(Pyrid-2-Yl) Amino Substituted Pyrimidine as Protein Kinase Inhibitors | IGF1R, IGFBP1, IRS1 | HCRTR1 4468/4885HCRTR2 4336/4885USP30 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.